Lenvik, Alexander J.
https://orcid.org/0000-0003-2870-917X
Mayo Clinic
Division of Hematology, Oncology, and Transplantation, Department of Medicine, and
Citations 1
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
Gleason, Michelle , Ross, Julie A. , Warlick, Erica D. , Wiernik, Andres , Haagenson, Michael , Lenvik, Alexander J. , Litzow, Mark R. , Epling‐Burnette, Pearlie K. , Weisdorf, Daniel J. , Vallera, Daniel A. , Miller, Jeffrey S. , Lund, Troy C. , Verneris, Michael R. , Spellman, Stephen R. , Blazar, Bruce R. , Weiner, Louis M. , Weisdorf, Dan , Miller, Jeffrey S
Blood | March 21, 2014 | Volume: 123 | Issue: 19 | Pages: 3016-3026
Key Points NK cells and their expression of FcRγIII (CD16) are decreased in MDS and inversely correlate with a substantial increase in MDSCs. CD16xCD33 BiKE potently activates blood and marrow MDS-NK cells at all diseases stages to lyse CD33+ MDS and CD33+ MDSC targets.